The companies share design of global Phase 3 trial, iMMagine-3; will evaluate anito-cel in patients exposed to both an immunomodulatory (lMiD) drug and an anti-CD38 monoclonal antibody --
-- Anito-cel will be manufactured from Kite’s Frederick, Maryland facility for iMMagine-3 as the successful technical transfer is complete --
-- Remain on track to present preliminary data from the iMMagine-1 trial by end of the year --
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.